Vaccine, Год журнала: 2023, Номер 42(10), С. 2543 - 2552
Опубликована: Ноя. 14, 2023
Bivalent mRNA vaccines were recommended since September 2022. However, coverage with a recent vaccine dose has been limited, and there are few robust estimates of bivalent VE against symptomatic SARS-CoV-2 infection (COVID-19). We estimated COVID-19 among eligible U.S. healthcare personnel who had previously received monovalent doses.
Язык: Английский
Nature Communications, Год журнала: 2023, Номер 14(1)
Опубликована: Сен. 20, 2023
The bivalent (original and Omicron BA.4/BA.5) mRNA-1273 COVID-19 vaccine was authorized to offer broader protection against COVID-19. We conducted a matched cohort study evaluate the effectiveness of in preventing hospitalization for (primary outcome) medically attended SARS-CoV-2 infection hospital death (secondary outcomes). Compared individuals who did not receive mRNA vaccination but received ≥2 doses any monovalent vaccine, relative (rVE) 70.3% (95% confidence interval, 64.0%-75.4%). rVE consistent across subgroups modified by time since last dose or number received. Protection durable ≥3 months after booster. requiring emergency department/urgent care 55.0% (50.8%-58.8%) 82.7% (63.7%-91.7%), respectively. booster provides additional COVID-19, infection, death.
Язык: Английский
Процитировано
45
Eurosurveillance, Год журнала: 2023, Номер 28(7)
Опубликована: Фев. 16, 2023
We used data of 32,542 prospective cohort study participants who previously received primary and one or two monovalent booster COVID-19 vaccinations. Between 26 September 19 December 2022, relative effectiveness bivalent original/Omicron BA.1 vaccination against self-reported Omicron SARS-CoV-2 infection was 31% in 18-59-year-olds 14% 60-85-year-olds. Protection higher than without prior infection. Although increases protection hospitalisations, we found limited added benefit preventing
Язык: Английский
Процитировано
34
Med, Год журнала: 2024, Номер 5(5), С. 401 - 413.e4
Опубликована: Апрель 3, 2024
Язык: Английский
Процитировано
13
Influenza and Other Respiratory Viruses, Год журнала: 2024, Номер 18(4)
Опубликована: Апрель 1, 2024
ABSTRACT Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID‐19 hospitalisation and death booster‐eligible ≥ 65‐year‐olds, during October–November 2023. We linked electronic records to construct retrospective cohorts used Cox models estimate adjusted hazard ratios derive VE. VE for was, respectively, 67% (95%CI: 58–74) 42–81) 65‐ 79‐year‐olds 66% 57–73) 72% 51–85) 80‐year‐olds. Results indicate that periodic vaccination of individuals 65 years has an ongoing benefit support current strategies EU/EEA.
Язык: Английский
Процитировано
11
International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(15), С. 8155 - 8155
Опубликована: Июль 26, 2024
At present, COVID-19 remains a public health concern due to the ongoing evolution of SARS-CoV-2 and its prevalence in particular countries. This paper provides an updated overview epidemiology pathogenesis COVID-19, with focus on emergence variants phenomenon known as ‘long COVID’. Meanwhile, diagnostic detection advances will be mentioned. Though many inventions have been made combat pandemic, some outstanding ones include multiplex RT-PCR, which can used for accurate diagnosis infection. ELISA-based antigen tests also appear potential tools available future. discusses current treatments, vaccination strategies, well emerging cell-based therapies The underscores necessity us continuously update scientific understanding treatments it.
Язык: Английский
Процитировано
10
Vaccine, Год журнала: 2024, Номер 42(15), С. 3389 - 3396
Опубликована: Апрель 22, 2024
Язык: Английский
Процитировано
9
Nature Communications, Год журнала: 2024, Номер 15(1)
Опубликована: Май 18, 2024
Abstract Waning antibody responses after COVID-19 vaccination combined with the emergence of SARS-CoV-2 Omicron lineage led to reduced vaccine effectiveness. As a countermeasure, bivalent mRNA-based booster vaccines encoding ancestral spike protein in combination that BA.1 or BA.5 were introduced. Since then, different BA.2-descendent lineages have become dominant, such as XBB.1.5, JN.1, EG.5.1. Here, we report post-hoc analyses data from SWITCH-ON study, assessing how priming regimens affect immunogenicity vaccinations and breakthrough infections (NCT05471440). boosted neutralizing antibodies T-cells up 3 months boost; however, cross-neutralization XBB.1.5 was poor. Interestingly, combinations prime-boost induced divergent responses: participants primed Ad26.COV2.S developed lower binding levels boost while neutralization T-cell similar participants. In contrast, breadth higher mRNA-primed Combined, our further support current use monovalent based on circulating strains when vaccinating risk groups, recently recommended by WHO. We emphasize importance continuous assessment immune targeting variants guide future policies.
Язык: Английский
Процитировано
9
Vaccines, Год журнала: 2023, Номер 11(11), С. 1711 - 1711
Опубликована: Ноя. 11, 2023
The emergence of Omicron variants coincided with declining vaccine-induced protection against SARS-CoV-2. Two bivalent mRNA vaccines, mRNA-1273.222 (Moderna) and BNT162b2 Bivalent (Pfizer-BioNTech), were developed to provide greater the predominate circulating by including that encodes both ancestral (original) strain BA.4/BA.5. We estimated their relative vaccine effectiveness (rVE) in preventing COVID-19-related outcomes US using a nationwide dataset linking primary care electronic health records pharmacy/medical claims data. study population (aged ≥18 years) received either between 31 August 2022 28 February 2023. used propensity score weighting adjust for baseline differences groups. rVE hospitalizations (primary outcome) outpatient visits (secondary) 1,034,538 1,670,666 recipients, an adjusted 9.8% (95% confidence interval: 2.6–16.4%) 5.1% CI: 3.2–6.9%), respectively, versus Bivalent. incremental was among adults ≥ 65; these patients 13.5% 5.5–20.8%) 10.7% (8.2–13.1%), respectively. Overall, we found compared visits, increased benefits older adults.
Язык: Английский
Процитировано
22
Eurosurveillance, Год журнала: 2024, Номер 29(37)
Опубликована: Сен. 12, 2024
BackgroundLong-term effectiveness data on bivalent COVID-19 boosters are limited.AimWe evaluated the long-term protection of against severe among ≥ 65-year-olds in Finland.MethodsIn this register-based cohort analysis, we compared risk three outcomes who received a booster (Original/Omicron BA.1 or Original/BA.4-5; exposed group) between 1/9/2022 and 31/8/2023 to those did not (unexposed). We included individuals vaccinated with at least two monovalent vaccine doses before 3 months ago. The analysis was divided into periods: 1/9/2022-28/2/2023 (BA.5 BQ.1.X predominating) 1/3/2023-31/8/2023 (XBB predominating). hazards for unexposed were Cox regression.ResultsWe 1,191,871 individuals. From 28/2/2023, associated reduced hospitalisation due (hazard ratio (HR): 0.45; 95% confidence interval (CI): 0.37-0.55), death (HR: 0.49; CI: 0.38-0.62), which contributing factor 0.40; 0.31-0.51) during 14-60 days since vaccination. 1/3/2023 31/8/2023, lower risks all 61-120 (e.g. HR: 0.53; 0.39-0.71 COVID-19); thereafter no notable reduction observed. No difference found Original/Omicron Original/BA.4-5 boosters.ConclusionBivalent initially by ca 50% 65-year-olds, but waned over time. These findings help guide development vaccination programmes.
Язык: Английский
Процитировано
7
International Journal of Infectious Diseases, Год журнала: 2024, Номер 142, С. 106986 - 106986
Опубликована: Фев. 26, 2024
The COVID-19 pandemic required rapid development of vaccines within a short period time which did not allow to assess vaccine effectiveness (VE) in the long-term.
Язык: Английский
Процитировано
6